Gerben C. M. Zondag
Directeur Général chez Synvolux Therapeutics BV
Profil
Gerben C.
M.
Zondag is currently the Chief Executive Officer at Synvolux Therapeutics BV and the Vice President-Technology Affairs at VitalneXt BV.
Previously, he worked as the Scientific Director & Operations Manager at Baseclear B.v and as the Vice President-Technology Affairs at DNage BV from 2006 to 2012.
He holds a doctorate degree from the University of Amsterdam, which he received in 1998.
Postes actifs de Gerben C. M. Zondag
| Sociétés | Poste | Début |
|---|---|---|
VitalneXt BV
 VitalneXt BV Pharmaceuticals: GenericHealth Technology VitalneXt BV develops retails and manufactures products for healthy ageing. Its products include promanna, vital01 and other products. The firm develops products with evidence-based health benefits for the ageing population. It also develops new, proprietary, technologies, ingredients and products through its own network and through collaborations with the company's research partners. The company was founded by Rein Strijker in May 2013 and is headquartered in Amersfoort, the Netherlands. | Corporate Officer/Principal | - |
Synvolux Therapeutics BV
 Synvolux Therapeutics BV Miscellaneous Commercial ServicesCommercial Services Synvolux Therapeutics BV provides drug delivery services. It is specialized in transporting of DNA, RNA (siRNA and RNAi) and proteins to the target destination. The company was founded in 2002 and is headquartered in Leiden, the Netherlands. | Directeur Général | - |
Anciens postes connus de Gerben C. M. Zondag
| Sociétés | Poste | Fin |
|---|---|---|
DNage BV
 DNage BV Miscellaneous Commercial ServicesCommercial Services DNage is a life sciences company founded in 2004 as a spin off from the Department of Genetics of the Erasmus Medical Center Rotterdam. The Company was seed-funded through an equity investment of an international syndicate of venture capitalists including LSP (NL) and Inventages (CH). The Company's main scientific founder Prof J. Hoeijmakers is a world-renowned scientist working on DNA repair and genome stability. His team was the first to establish an explicit connection between DNA damage (lack of repair) and the process of ageing, a scientific breakthrough. DNage has acquired exclusive access to this technology and now focuses on developing therapies to reduce the effects of ageing, leveraging the unique technologies developed by its founders. DNage has matured from an early stage technology company into a drug development company with ongoing clinical trials and several research programs. It has been acquired by Pharming Group NV in October 2006 and is currently involved in a financing round whereby Pharming will reduce its ownership to a non-controlling stake. The team of the company consists of approximately 15 people. DNage has laboratory facilities and offices in Rotterdam and Leiden, The Netherlands. | Corporate Officer/Principal | 21/08/2012 |
| Baseclear B.v | Directeur Technique/Scientifique/R&D | - |
Formation de Gerben C. M. Zondag
| University of Amsterdam | Doctorate Degree |
Expériences
Fonctions occupées
Actives
Inactives
Sociétés cotées
Entreprise privées
Relations
Relations au 1er degré
Entreprises liées au 1er degré
Homme
Femme
Administrateurs
Exécutifs
Sociétés liées
| Entreprise privées | 4 |
|---|---|
DNage BV
DNage BV Miscellaneous Commercial ServicesCommercial Services DNage is a life sciences company founded in 2004 as a spin off from the Department of Genetics of the Erasmus Medical Center Rotterdam. The Company was seed-funded through an equity investment of an international syndicate of venture capitalists including LSP (NL) and Inventages (CH). The Company's main scientific founder Prof J. Hoeijmakers is a world-renowned scientist working on DNA repair and genome stability. His team was the first to establish an explicit connection between DNA damage (lack of repair) and the process of ageing, a scientific breakthrough. DNage has acquired exclusive access to this technology and now focuses on developing therapies to reduce the effects of ageing, leveraging the unique technologies developed by its founders. DNage has matured from an early stage technology company into a drug development company with ongoing clinical trials and several research programs. It has been acquired by Pharming Group NV in October 2006 and is currently involved in a financing round whereby Pharming will reduce its ownership to a non-controlling stake. The team of the company consists of approximately 15 people. DNage has laboratory facilities and offices in Rotterdam and Leiden, The Netherlands. | Commercial Services |
| Baseclear B.v | |
VitalneXt BV
VitalneXt BV Pharmaceuticals: GenericHealth Technology VitalneXt BV develops retails and manufactures products for healthy ageing. Its products include promanna, vital01 and other products. The firm develops products with evidence-based health benefits for the ageing population. It also develops new, proprietary, technologies, ingredients and products through its own network and through collaborations with the company's research partners. The company was founded by Rein Strijker in May 2013 and is headquartered in Amersfoort, the Netherlands. | Health Technology |
Synvolux Therapeutics BV
Synvolux Therapeutics BV Miscellaneous Commercial ServicesCommercial Services Synvolux Therapeutics BV provides drug delivery services. It is specialized in transporting of DNA, RNA (siRNA and RNAi) and proteins to the target destination. The company was founded in 2002 and is headquartered in Leiden, the Netherlands. | Commercial Services |
